AGENDA

Friday 13th of September 2019

7:00 am - 8:30 am Welcome Desk
Registration and Opening Remarks

8:30 am - 8:45 am OPENING INTRODUCTION

BREAST CANCER (8:45 am - 10:15 am)
Chair Persons: Aydah Al Awadhi, Dr. Humaid Al Shamsi

BREAST CANCER - 503
Impact of clinical risk category on prognosis and prediction of chemotherapy benefit in early breast cancer (EBC) by age and the 21-gene recurrence score (RS) in TAILORx.
- Presented by: Dr. Nuhad Ibrahim

BREAST CANCER - 1000
SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) chemotherapy (C) versus trastuzumab (T) C in patients (pts) with HER2 metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx).
- Presented by: Dr. Nuhad Ibrahim

BREAST CANCER - 1002
Neratinib capecitabine versus lapatinib capecitabine in patients with HER2 metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial.
- Presented by: Dr. Nuhad Ibrahim

BREAST CANCER - 1003
IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC).
- Presented by: Dr. Nuhad Ibrahim

BREAST CANCER - LBA1008
Phase III MONALEESA-7 trial of premenopausal patients with HR /HER2– advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results.
- Presented by: Dr. Faisal Al Terkait
**BREAST CANCER - 1038**

**Alpelisib (ALP) with fulvestrant (FUL) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Primary or secondary resistance to prior endocrine therapy (ET) in the SOLAR-1 trial.**

- **Presented by: Dr. Anwar Al Nouri**

**BREAST CANCER - 1039**

**Patient-reported outcomes (PROs) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) from SOLAR-1.**

- **Presented by: Dr. Hope Rugo**

**BREAST CANCER - 1040**

**Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor-2-negative (HER2-) advanced breast cancer (ABC): First interim BYLieve study results.**

- **Presented by: Dr. Hope Rugo**

**PANEL QUESTIONS & ANSWERS**

**10:15 - 10:35  COFFEE BREAK**

**10:35 - 11:05  AMGEN SYMPOSIUM**

**GYNECOLOGIC CANCER (11:05 am - 11:30 am)**

**Chair Person: Dr. Falah Al Khatib**

**GYNECOLOGIC CANCER - 5500**

**A randomized phase 3 trial of paclitaxel (P) plus carboplatin (C) versus paclitaxel plus ifosfamide (I) in chemotherapy-naive patients with stage I-IV, persistent or recurrent carcinosarcoma of the uterus or ovary: An NRG oncology trial.**

- **Presented by: Dr. Hassan Jaafar**

**GYNECOLOGIC CANCER - 5505**

**Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer. A randomized controlled chemotherapy-free study—NSGO-AVANOVA2/ENGOT-OV24.**

- **Presented by: Dr. Hassan Jaafar**

**PANEL QUESTIONS & ANSWERS**
MELANOMA (11:30 am - 12:00 pm)
Chair Person: Dr. Urfan Ul Haq

MELANOMA/SKIN CANCERS, SARCOMA, SYMPTOMS AND SURVIVORSHIP - 2512
Ipilimumab versus placebo after complete resection of stage III melanoma: Long-term follow-up results the EORTC 18071 double-blind phase 3 randomized trial.
- Presented by: Dr. Dima Abduljabbar

MELANOMA/SKIN CANCERS, SARCOMA, SYMPTOMS AND SURVIVORSHIP - 9501
Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204).
- Presented by: Dr. Dima Abduljabbar

PANEL QUESTIONS & ANSWERS

12:00 - 2:00 PRAYER AND LUNCH BREAK
A bus will be available to take you to the nearest Mosque at prayer time.

2:00 - 3:00 PFIZER SATELLITE SYMPOSIUM (Parallel session by invitation only)

SYMPTOMS AND SURVIVORSHIP (2:00 pm - 3:00 pm)
Chair Person: Dr. Abdelsalam Al Najjar

SYMPTOMS AND SURVIVORSHIP - 6509
The impact of routine ESAS use on overall survival: Results of a population-based retrospective matched cohort analysis.
- Presented by: Dr. Mona Tareen

SYMPTOMS AND SURVIVORSHIP - 11507
- Presented by: Dr. Mona Tareen

SYMPTOMS AND SURVIVORSHIP - 11506
Safety of pregnancy following breast cancer (BC) in patients (pts) carrying a BRCA mutation (mBRCA): Results of an international cohort study.
- Presented by: Dr. Aydah Al-Awadhi

SYMPTOMS AND SURVIVORSHIP - 11514
A randomized controlled trial of a novel artificial intelligence-based smartphone application to optimize the management of cancer-related pain.
- Presented by: Dr. Aydah Al-Awadhi
SYMPTOMS AND SURVIVORSHIP - 11503

A randomized, double-blind, placebo-controlled phase III trial evaluating olanzapine 5 mg combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy: J-FORCE Study.

- Presented by: Dr. Aydah Al-Awadhi

PANEL QUESTIONS & ANSWERS

LUNG CANCER (3:00 pm - 4:10 pm)
Chair Person: Dr. Syed Hammad Tirmazy & Abdelaziz Al Farsi

LUNG CANCER - 8503
Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3).
- Presented by: Dr. Fathi Azribi

LUNG CANCER - 8504
Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study.
- Presented by: Dr. Fathi Azribi

LUNG CANCER - 8506
Efficacy and safety profile of Lurbinectedin in second-line SCLC patients: Results from a phase II single-agent trial.
- Presented by: Dr. Fathi Azribi

LUNG CANCER - 9000
RELAY: A multicenter, double-blind, randomized Phase 3 study of erlotinib in combination with ramucirumab or placebo in previously untreated patients with epidermal growth factor receptor mutation-positive metastatic non-small cell lung cancer.
- Presented by: Dr. Rosario García Campelo

LUNG CANCER - 9001
Gefitinib versus gefitinib-pemetrexed-carboplatin in EGFR mutated lung cancer (Gef vs. Gef + C).
- Presented by: Dr. Rosario García Campelo

LUNG CANCER - 9002
ECOG-ACRIN 5508: Pemetrexed, bevacizumab or the combination as maintenance therapy for advanced non-squamous non-small cell lung cancer.
- Presented by: Dr. Rosario García Campelo

PANEL QUESTIONS & ANSWERS

4:10 - 4:30  COFFEE BREAK
Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

- Presented by: Dr. Diaeddine Trad

TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

- Presented by: Dr. Diaeddine Trad

Gemcitabine and cisplatin (GP) induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT) versus CCRT alone in locoregionally advanced nasopharyngeal carcinoma (NPC): A phase 3, multicenter, randomized controlled trial.

- Presented by: Dr. Aref Chehal

Primary analysis of Phase 2 results of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with locally advanced cutaneous squamous cell carcinoma (laCSCC).

- Presented by: Dr. Aref Chehal

PANEL QUESTIONS & ANSWERS

5:20 - 6:00  BMS SYMPOSIUM - Chairperson: Dr. Humaid Al Shamsi - Presented by: Dr. Emad Dawoud
GASTROINTESTINAL NON COLORECTAL CANCER (8:30 am - 8:40 am)
Chair Persons: Dr. Humaid Al Shamsi & Dr. Bassim Al Bahrani

GASTROINTESTINAL CANCER - LBA4 - PLENARY SESSION
Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial.
- Presented by: Dr. Robert Wolff

GASTROINTESTINAL CANCER - 4000
APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma.
- Presented by: Dr. Robert Wolff

GASTROINTESTINAL CANCER - 4003
ABC-06 I A randomised phase III, multi-centre, open-label study of Active Symptom Control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.
- Presented by: Dr. Robert Wolff

8:40 - 9:10 SERVIER SYMPOSIUM

GASTROINTESTINAL COLORECTAL CANCER (9:10 am - 9:45 am)
Chair Persons: Dr. Humaid Al Shamsi & Dr. Bassim Al Bahrani

GASTROINTESTINAL CANCER - 3501
Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC).
- Presented by: Dr. Jasem El Barrak

GASTROINTESTINAL CANCER - 3504
FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer.
- Presented by: Dr. Jasem El Barrak

GASTROINTESTINAL CANCER - 3508
Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the first- and second-line treatment of unresectable mCRC.
- Presented by: Dr. Jasem El Barrak
GENITOURINARY: PROSTATE AND NON-PROSTATE CANCER  
(11:00 am - 12:30 pm)  
Chair Persons: Dr. Fariborz Bagheri & Dr. Norbert Dreier

---

GENITOURINARY CANCER - LBA2 - PLENARY  
Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial.  
- Presented by: Dr. Syed Hammad Tirmazy

---

GENITOURINARY CANCER - 5006  
First results from TITAN: A phase III double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).  
- Presented by: Dr. Syed Hammad Tirmazy

---

GENITOURINARY CANCER - 5008  
Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC).  
- Presented by: Dr. Syed Hammad Tirmazy

---

GENITOURINARY CANCER - 4500  
Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.  
- Presented by: Dr. Jawaher Ansari

---

GENITOURINARY CANCER - LBA4 - 4505  
EV-201: Results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and immune checkpoint inhibitors.  
- Presented by: Dr. Jawaher Ansari

---

GENITOURINARY CANCER - 4574  
Consistent efficacy of nivolumab plus ipilumab across number of IMDC risk factors.  
- Presented by: Dr. Emad Dawoud

---

GENITOURINARY CANCER - 4513  
Posthoc analyses of nivolumab plus ipilumab or sunitinib in IMDC inter/poor risk previously untreated aRCC with sarcomatoid features.  
- Presented by: Dr. Emad Dawoud
Safety and efficacy of nivolumab plus ipilumab in patients with a RCC with brain metastases.

- Presented by: Dr. Emad Dawoud

PANEL QUESTIONS & ANSWERS

12:30 - 1:30  LUNCH BREAK

1:30 - 2:00  BMS SYMPOSIUM

CENTRAL NERVOUS SYSTEM (2:00 pm - 2:50 pm)
Chair Persons: Dr. Imad Hachem

Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion.

- Presented by: Dr. Muhammad Farooq Latif

Randomized phase IIb clinical trial of continuation or non-continuation with six cycles of temozolomide after the first six cycles of standard first-line treatment in patients with glioblastoma: A Spanish research group in neuro-oncology (GEINO) trial.

- Presented by: Dr. Muhammad Farooq Latif

Updated predictive analysis of the WHO-defined molecular subgroups of low-grade gliomas within the high-risk treatment arms of NRG Oncology/RTOG 9802.

- Presented by: Dr. Tarek Dufan

Single agent ONC201 in adult recurrent H3 K27M-mutant glioma.

- Presented by: Dr. Tarek Dufan

PANEL QUESTIONS & ANSWERS

2:50 - 3:10  COFFEE BREAK

HEMATOLOGIC MALIGNANCY (3:10 pm - 4:20 pm)
Chair Persons: Dr. Hassan Jaafar & Dr. Maroun El Khoury

Effect of gilteritinib on survival in patients with FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) AML who have common AML co-mutations or a high FLT3-ITD allelic ratio.

- Presented by: Dr. Asma Al Olama
Effect of fixed-duration venetoclax plus obinutuzumab (VenG) on progression-free survival (PFS), and rates and duration of minimal residual disease negativity (MRD–) in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) and comorbidities.
- Presented by: Dr. Asma Al Olama

Rituximab maintenance for patients with diffuse large B-cell lymphoma in first complete remission: Results from a randomized HOVON-Nordic Lymphoma Group phase III study.
- Presented by: Dr. Faraz Khan

E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma.
- Presented by: Dr. Faraz Khan

A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM).
- Presented by: Dr. Mahmoud Marashi

Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory multiple myeloma (RRMM): COLUMBA.
- Presented by: Dr. Mahmoud Marashi

PANEL QUESTIONS & ANSWERS

4:20 - 4:30 CLOSING REMARKS